• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Annual Changes to the Nasdaq-100 Index®

    12/13/24 8:00:00 PM ET
    $AXON
    $ILMN
    $MRNA
    $MSTR
    Ordnance And Accessories
    Industrials
    Medical Specialities
    Health Care
    Get the next $AXON alert in real time by email

    NEW YORK, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX), which will become effective prior to market open on Monday, December 23, 2024.

    The following three companies will be added to the Index: Palantir Technologies Inc. (NASDAQ:PLTR), MicroStrategy Incorporated (NASDAQ:MSTR), and Axon Enterprise, Inc. (NASDAQ:AXON).

    The Nasdaq-100 Index® is composed of 100 of the largest non-financial companies1 listed on The Nasdaq Stock Market® and dates to January 1985 – nearly 40 years ago –when it was launched along with the Nasdaq Financial-100™ Index, which is comprised of 100 of the largest financial stocks on Nasdaq® These indexes act as benchmarks for financial products such as options, futures, and funds. The Nasdaq-100® is reconstituted each year in December, timed to coincide with the quadruple witch expiration Friday of the quarter.

    The Nasdaq-100 Index® is the basis of the Invesco QQQ Trust (NASDAQ:QQQ) which aims to provide investment results that, before expenses, correspond with the Nasdaq-100 Index® performance. In addition, options, futures and structured products based on the Nasdaq-100 Index® and the Invesco QQQ Trust trade on various exchanges.

    As a result of the reconstitution, the following three companies will be removed from the Index: Illumina, Inc. (NASDAQ:ILMN), Super Micro Computer, Inc. (NASDAQ:SMCI), and Moderna, Inc. (NASDAQ:MRNA).

    Information

    For information about the three companies to be added to the Nasdaq-100 Index®, please visit the following respective company websites:

    Palantir Technologies Inc. – https://www.palantir.com/

    MicroStrategy Incorporated – https://www.microstrategy.com/

    Axon Enterprise, Inc. – https://www.axon.com/

    About Nasdaq Global Indexes

    Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse. We continuously offer new opportunities for financial product sponsors across a wide spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide.

    _______________

    1 As outlined in the Nasdaq-100 Index® Methodology

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X, or at www.nasdaq.com. 

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The Nasdaq OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG - 

    Media Relations Contact Investor Relations Contact 
    Name: Jennifer Lawson

    Email: [email protected]

     Name: Index Client Services

    Email: [email protected]

     
        


    Primary Logo

    Get the next $AXON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXON
    $ILMN
    $MRNA
    $MSTR

    CompanyDatePrice TargetRatingAnalyst
    Axon Enterprise Inc.
    $AXON
    9/24/2025$893.00Overweight
    Piper Sandler
    Super Micro Computer Inc.
    $SMCI
    9/16/2025$46.00Mkt Perform
    Bernstein
    Illumina Inc.
    $ILMN
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    Axon Enterprise Inc.
    $AXON
    8/5/2025$900.00Hold → Buy
    Craig Hallum
    Palantir Technologies Inc.
    $PLTR
    8/5/2025$160.00Sell → Hold
    Deutsche Bank
    Palantir Technologies Inc.
    $PLTR
    7/25/2025$170.00Overweight
    Piper Sandler
    Nasdaq Inc.
    $NDAQ
    7/25/2025$115.00Neutral → Buy
    UBS
    Axon Enterprise Inc.
    $AXON
    7/16/2025$820.00Neutral
    UBS
    More analyst ratings

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Partovi Hadi bought $1,004,920 worth of shares (1,358 units at $740.00), increasing direct ownership by 0.57% to 237,938 units (SEC Form 4)

    4 - AXON ENTERPRISE, INC. (0001069183) (Issuer)

    8/15/25 4:36:59 PM ET
    $AXON
    Ordnance And Accessories
    Industrials

    Director Briger Peter L Jr bought $19,800,000 worth of Series A Perpetual Stretch Preferred Stock (220,000 units at $90.00) (SEC Form 4)

    4 - MICROSTRATEGY Inc (0001050446) (Issuer)

    7/29/25 6:20:52 PM ET
    $MSTR
    Computer Software: Prepackaged Software
    Technology

    President & CEO Le Phong bought $495,000 worth of Series A Perpetual Stretch Preferred Stock (5,500 units at $90.00) (SEC Form 4)

    4 - MICROSTRATEGY Inc (0001050446) (Issuer)

    7/29/25 4:55:28 PM ET
    $MSTR
    Computer Software: Prepackaged Software
    Technology

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Illumina launches new business to accelerate technology and data-driven discovery

    New business focuses on developing data assets, software, and AI to fuel life science breakthroughs Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and interpret ever larger-scale multiomic data. By bringing together Illumina's strengths across sequencing, data analysis, software and AI, BioInsight will empower customers and partners with solutions to identify drug targets, under

    10/1/25 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

    Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple Myeloma Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first

    10/1/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Nasdaq to Hold Third Quarter 2025 Investor Conference Call

    NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ: NDAQ) has scheduled its third quarter 2025 financial results announcement.   Who:Nasdaq's CEO, CFO, and additional members of its senior management team  What:Review Nasdaq's third quarter 2025 financial results  When:Tuesday, October 21, 2025 Results Call: 8:00 AM ET   Senior management will be available for questions from the investment community following prepared remarks. All participants can access the conference via webcast through the Nasdaq Investor Relations website at http://ir.nasdaq.com/. Note: The press release and results presentation for the third quarter 2025 results will be posted on the Nasdaq Investor Relatio

    9/29/25 4:15:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AXON
    $ILMN
    $MRNA
    $MSTR
    SEC Filings

    View All

    SEC Form SC TO-C filed by Moderna Inc.

    SC TO-C - Moderna, Inc. (0001682852) (Subject)

    10/3/25 9:20:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form PRE 14A filed by Moderna Inc.

    PRE 14A - Moderna, Inc. (0001682852) (Filer)

    10/3/25 7:30:45 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Invesco QQQ Trust, Series 1

    DEFA14A - INVESCO QQQ TRUST, SERIES 1 (0001067839) (Filer)

    9/30/25 4:03:29 PM ET
    $QQQ

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Axon with a new price target

    Piper Sandler initiated coverage of Axon with a rating of Overweight and set a new price target of $893.00

    9/24/25 7:55:50 AM ET
    $AXON
    Ordnance And Accessories
    Industrials

    Bernstein initiated coverage on Super Micro Computer with a new price target

    Bernstein initiated coverage of Super Micro Computer with a rating of Mkt Perform and set a new price target of $46.00

    9/16/25 8:10:38 AM ET
    $SMCI
    Computer Manufacturing
    Technology

    Illumina downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Illumina from Outperform to Neutral and set a new price target of $94.00

    8/12/25 7:55:50 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $AXON
    $ILMN
    $MRNA
    $MSTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Leadership Updates

    Live Leadership Updates

    View All

    Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

    Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple Myeloma Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first

    10/1/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Lambda Appoints Heather Planishek to Board of Directors as Audit Chair

    Industry veteran brings deep financial and operational expertise from Tines and Palantir Lambda, the Superintelligence Cloud, today announced the appointment of Heather Planishek to its Board of Directors, where she will serve as Audit Chair. Planishek brings extensive experience scaling high-growth technology companies, currently serving as Chief Operating and Financial Officer at Tines, the intelligent workflow platform. She previously served as Chief Accounting Officer at Palantir Technologies Inc. (NASDAQ: PLTR), where she guided the company through a period of significant growth and its transition to the public markets. This press release features multimedia. View the full release h

    9/25/25 8:00:00 AM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

    Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

    9/18/25 9:15:00 AM ET
    $ALNY
    $ILMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moore Alexander D. sold $3,680,225 worth of shares (20,000 units at $184.01), decreasing direct ownership by 2% to 1,252,978 units (SEC Form 4)

    4 - Palantir Technologies Inc. (0001321655) (Issuer)

    10/3/25 8:03:09 PM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    EVP, CSO Skule Jeremy sold $185,703 worth of shares (2,105 units at $88.22) and covered exercise/tax liability with 1,262 shares, decreasing direct ownership by 4% to 87,079 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    10/3/25 4:00:08 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Director Ullem Scott B. was granted 252 shares, increasing direct ownership by 3% to 8,389 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    10/2/25 4:06:14 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Financials

    Live finance-specific insights

    View All

    Nasdaq to Hold Third Quarter 2025 Investor Conference Call

    NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ: NDAQ) has scheduled its third quarter 2025 financial results announcement.   Who:Nasdaq's CEO, CFO, and additional members of its senior management team  What:Review Nasdaq's third quarter 2025 financial results  When:Tuesday, October 21, 2025 Results Call: 8:00 AM ET   Senior management will be available for questions from the investment community following prepared remarks. All participants can access the conference via webcast through the Nasdaq Investor Relations website at http://ir.nasdaq.com/. Note: The press release and results presentation for the third quarter 2025 results will be posted on the Nasdaq Investor Relatio

    9/29/25 4:15:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Supermicro Announces Fourth Quarter and Full Fiscal Year 2025 Financial Results

    Super Micro Computer, Inc. (NASDAQ:SMCI) ("Supermicro" or the "Company"), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, today announced unaudited financial results for its fourth quarter and full fiscal year ended June 30, 2025. Fourth Quarter Fiscal Year 2025 Highlights Net sales of $5.8 billion versus $4.6 billion in Q3'25 and $5.4 billion in Q4'24. Gross margin of 9.5% versus 9.6% in Q3'25 and 10.2% in Q4'24. Net income of $195 million versus $109 million in Q3'25 and $297 million in Q4'24. Diluted net income per common share of $0.31 versus $0.17 in Q3'25 and $0.46 in Q4'24. Non-GAAP diluted net income per common share of $0.41 versus $0.31 in Q3

    8/5/25 4:05:00 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    Axon reports Q2 2025 revenue of $669 million, up 33% year over year

    SCOTTSDALE, Ariz., Aug. 4, 2025 /PRNewswire/ -- Software & Services revenue grows 39% to $292 millionAnnual recurring revenue grows 39% to $1.2 billionNet income of $36 million supports non-GAAP net income of $174 million and Adjusted EBITDA of $172 millionRaises full year revenue outlook to a range of $2.65 billion to $2.73 billion, up from $2.60 billion to $2.70 billion.Fellow shareholders, Axon closed the first half of 2025 with record quarterly revenue, reflecting consistent execution and a strong foundation for long-term growth. Second quarter revenue grew 33% year over y

    8/4/25 4:01:00 PM ET
    $AXON
    Ordnance And Accessories
    Industrials

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by MicroStrategy Incorporated

    SC 13G - MICROSTRATEGY Inc (0001050446) (Subject)

    11/14/24 6:24:12 PM ET
    $MSTR
    Computer Software: Prepackaged Software
    Technology